Adipogen/N-Methyl-1-deoxynojirimycin/BVT-0130-M001/1 mg
商品编号：
BVT-0130-M001
品牌：
Adipogen Inc
市场价：
¥1900.00
美元价：
1140.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | N-Methyl-dNM; N-Methylmoranoline; MOR-14; 1,5-Dideoxy-1,5-(methylimino)-D-glucitol |
| Product Type | Chemical |
| Properties | |
| Formula | C7H15NO4 |
| MW | 177.2 |
| CAS | 69567-10-8 |
| Source/Host Chemicals | Isolated from Streptomyces sp. |
| Purity Chemicals | ≥98% (HPLC, 1H-NMR) |
| Appearance | White solid. |
| Solubility | Soluble in DMSO or water. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by BioViotica. |
| InChi Key | AAKDPDFZMNYDLR-XZBKPIIZSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light when in solution. |
| Use/Stability | Stable for at least 1 year after receipt when stored at +4°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- α-Glucosidase inhibitor.
- Glucosidase I inhibitor (IC50=0.3μM), 10-fold more potent over 1-Deoxynojirimycin (dNM).
- Inhibitor of glycoprotein processing.
- Strong glycosyltransferase (GTF) inhibitor.
- Angiogenesis inhibitor.
- Reduces the size of myocardial infarcts.
Product References
- N-methyl-1-deoxynojirimycin, a novel inhibitor of glycoprotein processing, and its effect on fowl plague virus maturation: P.A. Romero, et al.; Virology 130, 238 (1983)
- Effect of N-methyl-1-deoxy-nojirimycin on the degradation of cellobiose by Cellulomonas cartalyticum: H. Sahm, et al.; Appl. Microbiol. Biotechnol. 20, 54 (1984)
- Purification by affinity chromatography of glucosidase 1, an endoplasmic reticulum hydrolase involved in the processing of asparagine-linked oligasaccharides: H. Hettkamp, et al.; Eur. J. Biochem. 142, 85 (1984)
- Comparison between 1-deoxynojirimycin and N-methyl-1-deoxynojirimycin as inhibitors of oligosaccharide processing in intestinal epithelial cells: P.A. Romero, et al.; Biochem. J. 226, 733 (1985)
- Different effects of glucosidase inhibitors 1-deoxynojirimycin, N-methyl-1-deoxynojirimycin and castanospermine on the glycosylation of rat alpha1-proteinase inhibitor and α1-acid glycoprotein: V. Gross, et al.; Biochem. J. 236, 853 (1986)
- Inhibition of myoblast fusion by the glucosidase inhibitor N-methyl-1-deoxynojirimycin, but not by the mannosidase inhibitor 1-deoxymannojirimycin: P.C. Holland, et al.; Biochem. J. 238, 335 (1986)
- The glycoprotein-processing inhibitors bromoconduritol and N-methyl-1-deoxynojirimycin alter the adhesion phenotype of skeletal myoblasts: G.C. Trudel, et al.; Biochem. Cell Biol. 68, 1411 (1990)
- Glucosidase I, a transmembrane endoplasmic reticular glycoprotein with a luminal catalytic domain: K. Shailubhai, et al.; J. Biol. Chem. 266, 16587 (1991)
- Subsite specificity of the active site of glucosyltransferases from Streptococcus sobrinus: K.S. Devulapalle & G. Mooser; J. Biol. Chem. 269, 11967 (1994)
- N-methyl-1-deoxynojirimycin (MOR-14), an α-glucosidase inhibitor, markedly reduced infarct size in rabbit hearts: M. Arai, et al.; Circ. Res. 97, 1290 (1998)
- N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction: Y. Nishida, et al.; Heart Vessels 15, 268 (2000)
- Combination of N-methyl-1-deoxynojirimycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits: D.-J. Wu, et al.; Circ. J. 65, 673 (2001)
- Role of protein kinase C in the reduction of infarct size by N-methyl-1-deoxynojirimycin, an α-1,6-glucosidase inhibitor: M. Arai, et al.; Br. J. Pharmacol. 135, 635 (2001)
- Biological study of the angiogenesis inhibitor N-(8-(3-ethynylphenoxy)octyl-1-deoxynojirimycin: Y. Zhao, et al.; Chem. Biol. Drug Des. 75, 570 (2010)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
